1.Critics on "Adjunctive Memantine Therapy for Cognitive Impairment in Chronic Schizophrenia: A Placebo-Controlled Pilot Study".
Psychiatry Investigation 2013;10(1):98-99
No abstract available.
Memantine
2.Influence of Media on Suicide: Proper Coverage of Media on Suicide Report.
Journal of Korean Medical Science 2014;29(11):1583-1585
No abstract available.
3.Patient Preference and Satisfaction in Decision-Making Process.
Journal of Korean Medical Science 2014;29(7):1030-1031
No abstract available.
*Anesthesia, General
;
Female
;
Humans
;
Male
;
*Patient Preference
;
*Patient Satisfaction
4.Evidence-Based Treatment for Depressive Disorder.
Psychiatry Investigation 2015;12(2):278-279
No abstract available.
Depressive Disorder*
5.Why Systematic Review rather than Narrative Review?.
Psychiatry Investigation 2015;12(3):417-419
No abstract available.
6.Triple Reuptake Inhibitors: A Premise and Promise.
David M MARKS ; Chi Un PAE ; Ashwin A PATKAR
Psychiatry Investigation 2008;5(3):142-147
On the horizon there is a new class of psychoactive medications which work by inhibiting the neuronal reuptake of serotonin, norepinephrine, and dopamine. There are multiple potential indications for these drugs. Research suggests that they may have a role in treating depressive disorders, and it is plausible they may have potential efficacy in obesity, addiction, and pain syndromes. The current review describes some of the molecules in development presently and explores the research relevant to possible clinical uses for this class of medications.
Depressive Disorder
;
Dopamine
;
Neurons
;
Norepinephrine
;
Obesity
;
Serotonin
7.Strategies to Find Candidate Genes for Bipolar Disorder.
Psychiatry Investigation 2009;6(4):316-316
No abstract available.
Bipolar Disorder
8.Strategies to Find Candidate Genes for Bipolar Disorder.
Psychiatry Investigation 2009;6(4):316-316
No abstract available.
Bipolar Disorder
9.The Potential Role of Monocyte Chemoattractant Protein-1 for Major Depressive Disorder.
Psychiatry Investigation 2014;11(3):217-222
The immune hypothesis of major depressive disorder (MDD) fits well with the supposed interaction between genetic and environmental factors in disorders with a complicated etiopathogenesis. It has been suggested that infectious diseases are associated with MDD in that cytokines may play a critical role as a key modulator in the transition between infection and the development of MDD. It has been also suggested that antidepressants have immunomodulatory effects on some cytokines and cytokine receptors, although the exact mechanism has not yet been fully elucidated. Among cytokines, monocyte chemoattractant protein-1 (MCP-1) is especially well known and has attracted considerable interest owing to its immunomodulatory functions. MCP-1 is expressed in highly regionalized neuronal areas in the brain, leading to kind of modulation of neuronal activity and neuroendocrine functions commonly seen in patients with MDD. Additionally, it is involved in the control of other cytokines that have been consistently proposed as associated with the development of MDD. It also has a possible role in the neurodegenerative process of a number of central nervous system (CNS) diseases. Hence, this paper draws from the perspective of immunology to offer several suggestions about the role of MPC-1 in the development of MDD.
Allergy and Immunology
;
Antidepressive Agents
;
Brain
;
Central Nervous System
;
Chemokine CCL2*
;
Communicable Diseases
;
Cytokines
;
Depression
;
Depressive Disorder, Major*
;
Humans
;
Neurons
;
Receptors, Cytokine
10.The Potential Role of Monocyte Chemoattractant Protein-1 for Major Depressive Disorder.
Psychiatry Investigation 2014;11(3):217-222
The immune hypothesis of major depressive disorder (MDD) fits well with the supposed interaction between genetic and environmental factors in disorders with a complicated etiopathogenesis. It has been suggested that infectious diseases are associated with MDD in that cytokines may play a critical role as a key modulator in the transition between infection and the development of MDD. It has been also suggested that antidepressants have immunomodulatory effects on some cytokines and cytokine receptors, although the exact mechanism has not yet been fully elucidated. Among cytokines, monocyte chemoattractant protein-1 (MCP-1) is especially well known and has attracted considerable interest owing to its immunomodulatory functions. MCP-1 is expressed in highly regionalized neuronal areas in the brain, leading to kind of modulation of neuronal activity and neuroendocrine functions commonly seen in patients with MDD. Additionally, it is involved in the control of other cytokines that have been consistently proposed as associated with the development of MDD. It also has a possible role in the neurodegenerative process of a number of central nervous system (CNS) diseases. Hence, this paper draws from the perspective of immunology to offer several suggestions about the role of MPC-1 in the development of MDD.
Allergy and Immunology
;
Antidepressive Agents
;
Brain
;
Central Nervous System
;
Chemokine CCL2*
;
Communicable Diseases
;
Cytokines
;
Depression
;
Depressive Disorder, Major*
;
Humans
;
Neurons
;
Receptors, Cytokine
Result Analysis
Print
Save
E-mail